- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00278616
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome
High Dose Cyclophosphamide & CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome (APS): A Phase I Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University, Feinberg School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years< 55 years at the time of pretransplant evaluation
- A or 6.12.B:
A) An established diagnosis of a definite primary APS by Sapporo criteria as follows:
- Positive LA and/or ACLA IgG or IgM on two separate measurements, AND
- Arterial, venous or small vessel thrombosis (confirmed by imaging or doppler studies or histopathology, with the exception of superficial venous thrombosis) OR pregnancy morbidity (defined as three or more embryonic losses, OR one or more premature birth due to preeclampsia or growth retardation, OR one or more fetal death)
B) APLA-positive Sneddon syndrome defined as an association of ischemic cerebrovascular events and a widespread livedo reticularis
3. Patients failed treatment with anticoagulation including warfarin, heparin/LMWH in the presence of positive LA and/or ACLA IgG, or IgM. Failure is defined as any of above described thromboembolic events (6.12.A-2 or 6.12.B) except for pregnancy morbidity while receiving therapeutic anticoagulation. Therapeutic anticoagulation is defined as at least 5000 U of regular heparin SQ BID, OR unfractionated IV heparin adjusted for therapeutic PTT, OR at least 40 mg of lovenox SQ QD (or equivalent LMWH), OR coumadin adjusted for INR of at least 2.0, documented within 1 month of a refractory event or within 3 months if patient was known to be previously stable PLUS in the opinion of the investigator the individual has been receiving adequate anticoagulation.
Exclusion Criteria:
- Poor performance (PS) status (ECOG >2) at the time of entry, unless decline of PS is due to the disease itself and considered to be reversible.
Significant end organ damage such as (not caused by APS):
LVEF<40% or deterioration of LVEF during exercise test on MUGA or echocardiogram.
- Untreated life-threatening arrhythmia.
- Active ischemic heart disease or heart failure.
- DLCO<40% or FEV1/FEV < 50%.
- Serum creatinine >2.5 or creatinine clearance <30ml/min.
Liver cirrhosis, transaminases >3x of normal limits or bilirubin >2.0 unless due to Gilbert disease.
3. HIV positive.
4.Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive treatment.
5. Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as (but not limited to) head and neck cancer, or stage I or II breast cancer will be considered on an individual basis.
6. Positive pregnancy test, inability or unable to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.
7. Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.
8. Inability to give informed consent.
9. Major hematological abnormalities such as platelet count less than 100,000/ul, ANC less than 1000/ul unless due to APS.
10. Failure to collect at least 2.0 x 106 CD34+ / kg cells.*
11. Patients who are already in a clinical trial for APS treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity; Survival;Disease improvement;Time to disease progression;
Time Frame: 5 years after transplant
|
5 years after transplant
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NU APS AUTO 2004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ANTIPHOSPHOLIPID SYNDROME
-
Cairo UniversityCompletedPrimary Antiphospholipid SyndromeEgypt
-
University of FloridaHoffmann-La RocheCompletedAntiphospholipid Antibody SyndromeUnited States
-
Hospital Universitario Pedro ErnestoCompletedAntiphospholipid Antibody Syndrome
-
Duke UniversityRecruitingAntiphospholipid SyndromeUnited States
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Hospital for...Active, not recruitingAntiphospholipid Syndrome (APS)United States
-
Ruijin HospitalRecruitingAntiphospholipid Syndrome (APS)China
-
University Hospital, RouenUnknownAntiphospholipid Syndrome (APS)France
-
University Hospital, AngersUnknownPrimary Antiphospholipid SyndromeFrance
-
Peking University People's HospitalRecruitingAntiphospholipid Syndrome in PregnancyChina
-
Assistance Publique - Hôpitaux de ParisRecruitingAnticoagulants | Antiphospholipid Syndrome in PregnancyFrance
Clinical Trials on Stem Cell Transplantation
-
Northwestern UniversityTerminated
-
National Heart Institute, MexicoNational Center of Blood Transfusion Mexico.UnknownAcute Myocardial InfarctionMexico
-
General Hospital of Chinese Armed Police ForcesWithdrawn
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...WithdrawnAnemia | Thrombocytopenia | Neutropenia | Hematopoietic/Lymphoid Cancer | Lymphopenia
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical University; Chongqing Maternal and...Withdrawn
-
Royan InstituteCompletedCerebral PalsyIran, Islamic Republic of
-
Children's Hospital of Chongqing Medical UniversityUnknownBronchopulmonary DysplasiaChina
-
Royan InstituteCompletedOsteoarthritisIran, Islamic Republic of